Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate‐to‐severe plaque psoriasis naïve to systemic treatment-Reference-Cited by-同舟云学术

Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate‐to‐severe plaque psoriasis naïve to systemic treatment

Published:2020-11-10 Issue:3 Volume:184 Page:548-550
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Leutz A.¹,Pinter A.²^ORCID,Thaçi D.³,Augustin M.⁴^ORCID,Schuster C.¹,Fotiou K.¹,Hundemer H.P.¹,Saure D.¹,Mrowietz U.⁵^ORCID,Reich K.⁶^ORCID

Affiliation:

1. Lilly Deutschland GmbH Bad Homburg Germany

2. University Clinic of Frankfurt am Main Department of Dermatology Venereology and Allergology Frankfurt am Main Germany

3. Institute and Comprehensive Center Inflammation Medicine University zu LübeckUniversity Hospital Schleswig‐Holstein Campus Lübeck Lübeck Germany

4. Institute for Health Services Research in Dermatology and Nursing (IVDP) University Medical Center Hamburg‐Eppendorf (UKE) Hamburg Germany

5. Psoriasis‐Center Department of Dermatology University Medical Center Schleswig‐Holstein Campus Kiel Kiel Germany

6. Translational Research in Inflammatory Skin Diseases Institute for Health Services Research in Dermatology and NursingUniversity Medical Center Hamburg‐Eppendorf, and Skinflammation Center Hamburg Germany

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.19558

Reference8 articles.

1. Definition of treatment goals for moderate to severe psoriasis: a European consensus

2. Head‐to‐head trials of systemic psoriasis therapies: a systematic review of study design and maximum acceptable treatment differences

3. A 24‐week multicentre, randomized, open‐label, parallel‐group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate‐to‐severe plaque psoriasis naive to systemic treatment